Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

Erik A. Imel, Anthony A. Portale, Michael P. Whyte et al.|The Lancet|2019

Cited by 375